Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATimus).
Latin America
cohort studies
medical oncology
thymoma
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
18
01
2021
accepted:
06
02
2021
pubmed:
18
3
2021
medline:
15
12
2021
entrez:
17
3
2021
Statut:
ppublish
Résumé
Thymomas are a group of rare neoplasms of the anterior mediastinum. The objective of this study was to describe the demographics, clinical characteristics and treatment approaches in Latin America. This was a retrospective multicenter cohort study including patients with histologically proven thymomas diagnosed between 1997 and 2018. Demographics, clinicopathological characteristics and therapeutic outcomes were collected locally and analyzed in a centralized manner. A total of 135 patients were included. Median age at diagnosis was 53 years old (19-84), 53.3% (n = 72) of patients were female and 87.4% had an ECOG performance score ranging from 0-1. A total of 47 patients (34.8%) had metastatic disease at diagnosis. Concurrent myasthenia gravis occurred in 21.5% of patients. Surgery was performed in 74 patients (54.8%), comprising 27 (20%) tumorectomies and 47 (34.8%) thymectomies. According to the Masaoka-Koga system, overall survival (OS) at five-years was 73.4%, 63.8% and 51%, at stages I-II, III-IVA and IVB, respectively (p = 0.005). Furthermore, patients with low lactate dehydrogenase (LDH) (≤373 IU/L) at baseline and myasthenia gravis concurrence showed significantly better OS (p = 0.001 and p = 0.008, respectively). In multivariate analysis, high LDH levels (HR 2.8 [95% confidence interval [CI]: 1.1-7.8]; p = 0.036) at baseline and not performing a surgical resection (HR 4.1 [95% CI: 1.3-12.7]; p = 0.016) were significantly associated with increased risk of death. Our data provides the largest insight into the clinical characteristics and outcomes of patients with thymomas in Latin America. Survival in patients with thymomas continues to be very favorable, especially when subjected to adequate local control.
Sections du résumé
BACKGROUND
Thymomas are a group of rare neoplasms of the anterior mediastinum. The objective of this study was to describe the demographics, clinical characteristics and treatment approaches in Latin America.
METHODS
This was a retrospective multicenter cohort study including patients with histologically proven thymomas diagnosed between 1997 and 2018. Demographics, clinicopathological characteristics and therapeutic outcomes were collected locally and analyzed in a centralized manner.
RESULTS
A total of 135 patients were included. Median age at diagnosis was 53 years old (19-84), 53.3% (n = 72) of patients were female and 87.4% had an ECOG performance score ranging from 0-1. A total of 47 patients (34.8%) had metastatic disease at diagnosis. Concurrent myasthenia gravis occurred in 21.5% of patients. Surgery was performed in 74 patients (54.8%), comprising 27 (20%) tumorectomies and 47 (34.8%) thymectomies. According to the Masaoka-Koga system, overall survival (OS) at five-years was 73.4%, 63.8% and 51%, at stages I-II, III-IVA and IVB, respectively (p = 0.005). Furthermore, patients with low lactate dehydrogenase (LDH) (≤373 IU/L) at baseline and myasthenia gravis concurrence showed significantly better OS (p = 0.001 and p = 0.008, respectively). In multivariate analysis, high LDH levels (HR 2.8 [95% confidence interval [CI]: 1.1-7.8]; p = 0.036) at baseline and not performing a surgical resection (HR 4.1 [95% CI: 1.3-12.7]; p = 0.016) were significantly associated with increased risk of death.
CONCLUSIONS
Our data provides the largest insight into the clinical characteristics and outcomes of patients with thymomas in Latin America. Survival in patients with thymomas continues to be very favorable, especially when subjected to adequate local control.
Identifiants
pubmed: 33729676
doi: 10.1111/1759-7714.13901
pmc: PMC8088938
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328-1335Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Thorac Dis. 2016 Sep;8(9):2464-2472
pubmed: 27746998
J Thorac Dis. 2017 Nov;9(11):4550-4560
pubmed: 29268525
Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5
pubmed: 12963221
Ann Surg Oncol. 2012 Jan;19(1):94-8
pubmed: 21879277
J Thorac Dis. 2016 Apr;8(4):738-43
pubmed: 27114842
Chin J Cancer. 2017 May 15;36(1):46
pubmed: 28506287
Oncol Lett. 2016 Jun;11(6):4177-4182
pubmed: 27313762
J Thorac Oncol. 2013 Jul;8(7):952-8
pubmed: 23594467
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S102-9
pubmed: 25396306
Br J Cancer. 2000 Jun;82(12):2022-3
pubmed: 10864212
Surg Today. 2005;35(10):805-11
pubmed: 16175459
Am Soc Clin Oncol Educ Book. 2014;:e367-73
pubmed: 24857125
J Clin Oncol. 1999 Jul;17(7):2280-9
pubmed: 10561285
Mt Sinai J Med. 1971 Nov-Dec;38(6):497-537
pubmed: 4941403
J Thorac Oncol. 2015 Feb;10(2):367-72
pubmed: 25616178
Am J Clin Pathol. 2006 Apr;125(4):542-54
pubmed: 16627265
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer. 2002 Jul 15;95(2):420-9
pubmed: 12124843
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1698-704
pubmed: 21847050
Melanoma Res. 2019 Feb;29(1):1-12
pubmed: 30308577
Thorac Cancer. 2021 May;12(9):1328-1335
pubmed: 33729676
Surg Today. 2013 May;43(5):461-6
pubmed: 22948665
J Clin Oncol. 2011 May 20;29(15):2060-5
pubmed: 21502559
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1710-6
pubmed: 21847052
J Thorac Oncol. 2010 Dec;5(12):2017-23
pubmed: 20978450
Ann Thorac Surg. 2010 Jan;89(1):245-52; discussion 252
pubmed: 20103246
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S260-5
pubmed: 20859116
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
J Clin Oncol. 2004 Feb 1;22(3):454-63
pubmed: 14752067
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S143-7
pubmed: 25396312
J Clin Oncol. 1996 Mar;14(3):814-20
pubmed: 8622029
Cancer Treat Rev. 2012 Aug;38(5):540-8
pubmed: 22244677
Medicine (Baltimore). 2014 Dec;93(28):e324
pubmed: 25526488
BMC Cancer. 2014 Feb 20;14:110
pubmed: 24552144
J Thorac Oncol. 2018 Mar;13(3):436-446
pubmed: 29191778
Cancer. 1987 Dec 1;60(11):2727-43
pubmed: 3677008
Eur J Cardiothorac Surg. 2014 Sep;46(3):361-8
pubmed: 24482389
Eur J Cardiothorac Surg. 2004 Aug;26(2):412-8
pubmed: 15296907